Resilient Argenx stock holds above $1,000 as trial success and acquisition reshape outlook

Argenx stock is trading above $1,000 in late August 2026 after positive Phase 3 myositis data, an FDA label expansion for VYVGART and the completed Forte Biosciences deal, while recent volatility follows a cluster of analyst rating changes.

Argenx (ISIN NL0010832176) stock traded at $1,023.21 at the Nasdaq close on August 28, 2026, reflecting a 3.37 percent pullback on the day but leaving the shares more than 21 percent higher year to date based on CBOE data as of August 29, 2026. Recent reporting shows the move came after a sharp rally that carried the stock to a new 12?month high on a wave of analyst upgrades and positive clinical news.

Shares consolidate above the $1,000 mark

According to a US trading snapshot for Argenx under the ticker ARGX, the stock ended at $1,023.21 on August 28, 2026, down $35.69 or 3.37 percent from the previous close, highlighting the volatility after its recent run. The same overview indicates that this price still sits close to a recent 12?month high, underscoring how much value has been created since the start of the year.

Data from a CBOE?linked quote page compiled on August 29, 2026 reports a US price of $1,023.12 for Argenx, a 5?day performance of negative 3.44 percent, a year?to?date change of negative 1.61 percent and an overall gain of 21.59 percent since January 1, 2026. This same summary highlights how the recent pullback follows a strong medium?term upswing, with the stock giving back only a small part of its prior advance.

A separate technical commentary on Argenx points to a current signal level at $1,023.21 with reference marks at $776.94, $876.29 and $977.63 in its trading framework, marking the latest price as well above earlier support zones. That analysis suggests that even after the recent drop, shares remain positioned in the upper part of their recent range, which helps explain the cluster of positive analyst commentary seen in August.

Fundamentals: strong growth from VYVGART and expanding pipeline

For the fundamental picture investors are focusing on the most recent first half and first quarter 2026 results, which the company reported in May and July 2026. In the first quarter of 2026 Argenx disclosed that revenue increased versus the corresponding period of 2025, driven largely by uptake of its autoimmune therapy VYVGART and its subcutaneous formulation VYVGART Hytrulo, which had received broader US approval earlier in 2026. The half?year 2026 update in July 2026 confirmed that this growth trend continued into the second quarter, with total revenue for the first six months of 2026 outpacing the first half of 2025 as VYVGART adoption deepened across generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).

In that July 23, 2026 half?year release, Argenx paired the stronger revenue trajectory with updated operating metrics, including higher research and development spending as it advanced multiple Phase 3 programs and integration costs related to its acquisition strategy. Management reiterated its 2026 guidance framework for key financial items such as operating expenses and cash burn, signaling confidence that the expanding VYVGART franchise can support continued investment while preserving a solid cash runway.

Current consensus expectations captured in late?August earnings estimate updates project further revenue and earnings growth in fiscal 2027 and beyond, reflecting assumptions that VYVGART and VYVGART Hytrulo can reach multi?billion?dollar peak sales across their approved and potential indications. Several analyst models referenced in August 2026 news flow frame peak sales for the VYVGART franchise in the tens of billions of dollars, citing the breadth of autoimmune conditions driven by pathogenic IgG antibodies and the company’s strategy to address them with efgartigimod?based therapies.

One reason the half?year 2026 figures matter so much is that they now incorporate early revenue from the expanded US label. In early May 2026 Argenx announced that the US Food and Drug Administration had approved an extension of both VYVGART and VYVGART Hytrulo to cover all adult patients living with generalized myasthenia gravis, substantially enlarging the addressable treated population compared with the original label. As a result, the company entered the second quarter of 2026 with a larger pool of potential patients, and this expansion is reflected in the sequential growth seen between the first quarter and first half 2026 revenue numbers.

Profitability remains an area of active debate in analyst notes because Argenx continues to prioritize growth and pipeline investment over near?term margins. In its first quarter 2026 report, the company showed that operating losses narrowed compared with the same quarter of 2025 as revenue grew faster than operating expenses, but net income remained negative. By the half?year 2026 update the operating loss over the first six months had improved when measured against the prior year’s period, though the company emphasized that it intends to continue investing aggressively in new indications and platform expansion, which could limit margin expansion in the near term.

Catalyst: positive ALKIVIA trial and Forte Biosciences acquisition

The most important 2026 catalyst for Argenx so far has been the success of its Phase 3 ALKIVIA trial of efgartigimod in autoimmune myositis, which delivered positive topline results reported on August 17, 2026. The press release listing notes that the study met its primary endpoint, demonstrating a statistically significant improvement in muscle strength and patient?reported outcomes in the treated group compared with placebo, without introducing unexpected safety signals. This result extends the potential of efgartigimod beyond gMG and CIDP into a third major neuromuscular indication.

Following the ALKIVIA announcement, a series of detailed presentations and commentaries highlighted that the trial’s subgroup analyses still supported a broad filing strategy, even though certain subsets contributed more strongly to the overall effect size. Market commentary in the days after August 17, 2026 argued that this dataset materially lowers the development risk for the myositis indication and strengthens the broader investment case for the VYVGART franchise, which already underpins the bulk of Argenx’s current revenue.

Another structural catalyst came through the company’s move to expand its pipeline via acquisition. Argenx completed the acquisition of Forte Biosciences, Inc. on August 27, 2026 after launching a tender offer earlier in the month. The completion notice explains that the deal brings in FB102, a first?in?class anti?CD122 antibody targeting a novel immunology mechanism, which Argenx plans to develop in autoimmune indications that complement its existing portfolio.

The acquisition builds on a July 27, 2026 announcement in which Argenx set out its rationale for acquiring Forte Biosciences and adding FB102 to its immunology pipeline, highlighting the potential to pair efgartigimod’s IgG?modulating mechanism with cytokine?targeting approaches in complex diseases. By closing the transaction in late August 2026, management has now converted that strategic concept into an integrated asset, and investors will watch closely for initial development plans and timelines in upcoming R&D updates and earnings calls.

With these two late?summer catalysts, Argenx has shifted its story from a single?product focus to a more diversified immune?modulation platform. The ALKIVIA success strengthens the case that efgartigimod can work across multiple IgG?mediated diseases, while FB102 offers a second high?potential pathway that could eventually support combination strategies or expand the addressable market beyond what VYVGART alone can reach.

Analyst sentiment and valuation context

The run?up that carried Argenx to a new 12?month high in late August 2026 was supported by a flurry of brokerage activity, with several firms raising their price targets into a range between roughly $1,100 and $1,230 and reiterating positive ratings. A compiled list of ratings changes from mid to late August 2026 shows multiple upgrades to buy or overweight and higher target prices in response to both the ALKIVIA data and the broader VYVGART growth trajectory.

One mid?August 2026 note cited in that compilation raised a 12?month target to $1,202 per share after modeling higher peak sales for VYVGART, while another increased its target to $1,215, framing Argenx as a top pick among large?cap immunology names. A separate update lifted a target to $1,150, emphasizing the derisking effect of the myositis data on the VYVGART opportunity set. Several analyst summaries within that same dataset highlight a consensus view that VYVGART could reach peak annual sales above $20 billion if it secures approvals across the full range of IgG?mediated autoimmune diseases under study.

Not all voices are uniformly optimistic. In late August 2026 at least one bank downgraded Argenx to a hold rating, citing the strong share?price performance and the need to balance upside from pipeline wins against execution and competitive risks. Nonetheless, that more cautious view has so far been outweighed by the number of positive rating changes and target price hikes, which collectively support the elevated valuation multiple at which the stock trades compared with the broader biotechnology sector.

This split in opinion creates a natural tension for investors: on one hand Argenx offers a rapidly growing commercial franchise with expanding labels and strong late?stage data, while on the other hand much of that success is now reflected in a four?digit share price that embeds ambitious long?term growth assumptions. With the stock at $1,023.21 on August 28, 2026 and several targets clustered between $1,150 and $1,230, the upside implied by bullish models remains meaningful but narrower than earlier in the year.

Product focus: VYVGART and VYVGART Hytrulo

Argenx’s flagship products VYVGART and VYVGART Hytrulo are FcRn?blocking antibody?based therapies derived from efgartigimod, designed to reduce pathogenic IgG antibodies implicated in autoimmune diseases. VYVGART is administered intravenously, while VYVGART Hytrulo combines efgartigimod with recombinant human hyaluronidase for subcutaneous administration, offering more convenient dosing for many patients. The therapies are currently approved in multiple markets for adult patients with generalized myasthenia gravis and in some regions for chronic inflammatory demyelinating polyneuropathy, and Argenx is pursuing additional indications including autoimmune myositis following the positive ALKIVIA trial.

The commercial narrative around VYVGART centers on its potential to become a backbone therapy across a wide panel of autoimmune diseases driven by IgG. The company’s strategy has been to demonstrate efficacy disease by disease, starting with gMG and then expanding into CIDP and myositis, while also exploring other neuromuscular and systemic diseases where IgG plays a central role. With each successful trial the addressable market grows, and the recent FDA decision in May 2026 to extend the US VYVGART labels to all adult gMG patients has accelerated this process by broadening eligibility within an already approved indication.

Stock takeaway and current trading snapshot

As of the US close on August 28, 2026, Argenx stock traded at $1,023.21 on the Nasdaq, down 3.37 percent on the day but still up strongly over the course of 2026 in US dollar terms. That level aligns closely with a parallel CBOE quote of $1,023.12 reported as of August 29, 2026, which also shows that the shares have gained 21.59 percent since January 1, 2026 even after a modest 3.44 percent decline over the latest five?day window. The combination of strong fundamental progress, positive late?stage trial data and the completed Forte Biosciences acquisition helps explain why Argenx can sustain a four?digit share price despite bouts of volatility.

Company facts

Company: Argenx SE
ISIN: NL0010832176
Ticker: ARGX
Exchange: Nasdaq (primary US listing), also traded on Euronext Brussels
Price (as of August 28, 2026, 4:00 p.m. ET): $1,023.21 USD
Sector / Industry: Biotechnology and medical research